A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 224 participants.

Also called NCT07100418

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 224 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07100418
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07100418. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-12 (actual); primary completion 2026-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia
Condition
Hyperlipidemia
Intervention (Drug)
HRS-7249 Injection
Intervention (Drug)
Sodium Chloride Injection
Lead sponsor
Fujian Shengdi Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07100418
Content hash
9a3bcb2eaa6c493c0f3c3c43cdbbc65620e9ad9e3668bcb8642d54e3a9b8223f